TNFRSF1B and neoplasm: For the subcutaneous tumour model, IgG isotype control antibody and anti‐TNFRSF1B antibody was injected intraperitoneally every 6 days, and the tumour volume was measured on day 5, 9, 12, 18, 24 and 30 after ID8 injection (Figure 6A).